Strimvelis is a gene therapy drug used for the treatment of the rare immune deficiency ADA-SCID. Information on the composition, application and effect of the gene therapy medicinal product is provided in the summary of the European Public Assessment Report (EPAR) for the authorization of the medicinal product by the European Medicines Agency (EMA).

European Medicines Agency (2016): Strimvelis. Zusammenfassung des EPAR für die Öffentlichkeit. Online Version (German)

Wird geladen